Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587

Benzinga · 1d ago
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $578 to $587.